Catalent and GelMEDIX form global partnership to advance iPSC-derived cell therapies for ocular and retinal diseases
Thursday, March 12, 2026
GelMEDIX and Catalent have entered a global partnership to support the development and clinical manufacturing of induced pluripotent stem cell (iPSC)-derived therapies aimed at treating ocular and retinal diseases.
Under the agreement, GelMEDIX will use Catalent’s Good Manufacturing Practice (GMP)-compliant iPSC lines and cell therapy manufacturing capabilities. The partnership will support the development of GelMEDIX’s regenerative therapies designed to restore vision.
Catalent will provide expertise in iPSC and cell therapy development, including process development, analytical development, process scale-up and GMP manufacturing. The company will support the production of GelMEDIX’s iPSC-derived therapies from early development through clinical stages.
The collaboration is expected to help advance GelMEDIX’s programmes focused on developing regenerative treatments for patients with vision-related disorders.
Source: catalent.com
